Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peficitinib effects on bone structure in rheumatoid arthritis
jRCTs071220070Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of peficitinib in rheumatoid arthritis (RA), sponsored by Astellas Pharma. Primary endpoint: Change in bone erosion volume by HR-pQCT. Started Nov 2022; status: active, not recruiting.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071220070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220070.